P673 The safety of rapid versus standard infliximab infusions in children with inflammatory bowel disease: a multi-centre retrospective cohort study

Abstract Background Rapid infliximab (IFX) infusions have shown to be safe in adults with inflammatory bowel disease (IBD), but data on its safety paediatric IBD is limited. This study aimed assess the frequency and timing of infusion reactions (IR) children who received rapid (1-h) vs. standard (2-h) IFX infusions. Methods retrospective cohort included patients 4-18 years old, treated between January 2006 - November 2021 at two tertiary centres (AMC VUmc) Amsterdam, Netherlands. The AMC protocol was adjusted from a 1-h post-infusion observation period July 2019, whereas VUmc only were administered without period. After merging both departments 2022, allocated primary outcome acute IR amongst Secondary outcomes timing, severity management IR. Results Totally, 297 (150 VUmc, 147 AMC) (221 Crohn’s disease; 65 ulcerative colitis; 11 IBD-unclassified) included, total 7500 maintenance IFX-infusions. No differences found receiving (16/115, 13.9% patients), (1/31, 3.2%) rates (11/151, 7.3%) (p= 0.105). difference (26/4383, 0.6% infusions) (9/3117, 0.3%) 0.083). Twenty-six 35 (74.3%) occurred during infusion, while nine (25.7%). All mild, requiring no intervention or oral medication. Conclusion did not result an increased compared that mild. Our resulted adjustment for all patients.